Pharmaceutical or nutraceutical self-emulsifying solid dispersion composition

Pending Publication Date: 2020-12-10
HUANA GLOBAL BIOTECH CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a delivery system for water-insoluble or poorly water-soluble drugs or nutraceuticals. The system includes a carrier selected from silicic acid, silicate, or a combination of both, together with a surfactant and a carbohydrate filler. The technical effects of this invention are that it improves the solubility and bioavailability of the drugs or nutraceuticals, leading to better absorption and effectiveness in the body.

Problems solved by technology

Several marketed drugs suffer from poor solubility, low permeability, rapid metabolism and elimination from the body along with poor safety and tolerability.
On the other hand, bioactive agents such as nutraceuticals may also have low or variable bioavailability, which may limit their effectiveness and lead to variations in their efficacy.
But the abundance of α-tocopherol in the human body attracts so much attention that leads to the neglection of non-tocopherol vitamin E molecules as topics for basic and clinical research.
However, the lack of understanding on the bioavailability and behavior of T3 in the human system hurdles the advancement of T3.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical or nutraceutical self-emulsifying solid dispersion composition
  • Pharmaceutical or nutraceutical self-emulsifying solid dispersion composition
  • Pharmaceutical or nutraceutical self-emulsifying solid dispersion composition

Examples

Experimental program
Comparison scheme
Effect test

example 1

1.1 Preparations of FT Compositions

[0053]By way of example, any of the FT compositions set forth in Table 1 can usefully be prepared to provide the dissolution, bioaccessibility, absorption, and pharmacokinetic analyses. The FT compositions were prepared from the ingredients including 1-20% T3, 1-20% carrier, 1-5% surfactant, 52-94% filler(s), such as isomalt, starch, lactose, cyclodextrin, isomaltodextrin, lactose+isomalt, lactose+maltodextrins, and lactose+cyclodextrins, and 3% binder (Table 1). The oil phase components, including T3 and surfactant, and the solid phase excipients, including carrier and filler, were well mixed separately. The solid phase excipients were added to the oil phase solution and well mixed. The binder was dissolved in a solvent, such as ethanol, and then added to and well mixed with the solid phase. Alternatively, the binder could be directly added to and mixed with the solid phase. The mixture was sieved and dried, and then passed through a mesh.

TABLE 1S...

example 2

Dissolution Tests of UNF and Various FT Compositions

2.1 Dissolution Test Procedures

[0056]The FT compositions and UNF T3, including 2.0 g formulated powder or 150 mg oil form, were exposed to 750 mL of the acid medium (0.025% SDS-HCl aqueous solution, prepared by dissolving 2.5 g of sodium dodecyl sulfate (SDS) and 83 mL of hydrochloric acid in 10 L of purified water, pH 1.2) followed by exposure to the buffer medium (sequentially add 250 mL of 0.20 M tribasic sodium phosphate to the fluid in the vessel with a total volume was equal to 1000 mL). The dissolution tests were performed in the media with pH 1.2 and 6.8 sequentially. The test solutions in the acid medium were sampled and filtered at 15 and 30 minutes, respectively, through a 0.45 μm syringe filter. After 30 minutes, 250 mL of 0.20 M tribasic sodium phosphate was added to form a buffer medium. Next, the test solutions were sampled after 30 minutes and filtered through a 0.45 μin syringe filter. The collected media were subj...

example 3

Bioaccessibility (Transcellular Absorption) Analysis Using Caco-2 Cell Model

3.1. Cell Culture

[0058]To investigate the transcellular absorption of T3 by enterocytes, Caco-2 cell model was used. Caco-2 cells were seeded to 0.4 μm transwell insert in 12 well plate. 1 mL of medium was added to the basolateral compartment and 0.5 mL of medium to the apical compartment. The cells were allowed to evenly distribute and attach to the plate button, and incubated at 37° C. with an atmosphere of 5% CO2 and 95% air.

3.2. Differentiation of Caco-2 Cell Lines

[0059]Caco-2 cells started to differentiation spontaneously when the cells reached 80% confluence and after a total culture period of around 14˜21 days they appeared dense microvilli on the apical side, characteristic of small intestinal enterocytes. To ensure the proper differentiation of culture cells, Trans-Epithelial Electrical Resistance (TEER) values were measured. The cultured cells with the values between 250Ω˜400Ω by Ohm Meter were use...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention pertains to a pharmaceutical, or nutraceutical, “self-emulsifying solid dispersion” composition for oral administration which contains (a) a drug or a nutraceutical that is water-insoluble or poorly water-soluble; (b) at least one surfactant; (c) one carrier selected from the group consisting of silicic acid, a silicate, or any combination thereof; and (d) at least one carbohydrate filler.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 62 / 857,926, filed Jun. 6, 2019, which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to a pharmaceutical or nutraceutical self-emulsifying solid dispersion (SESD) composition.BACKGROUND OF THE INVENTION[0003]There are about 40% of approved drugs and nearly 90% of the developmental pipeline drugs consisting of poorly soluble molecules. Several marketed drugs suffer from poor solubility, low permeability, rapid metabolism and elimination from the body along with poor safety and tolerability.[0004]On the other hand, bioactive agents such as nutraceuticals may also have low or variable bioavailability, which may limit their effectiveness and lead to variations in their efficacy. For example, vitamin E, which is essential component of the human diet because the body cannot manufacture vitam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/10A61K31/355A61K47/26A61K47/10A61K47/44A61K47/40A61K47/02
CPCA61K47/44A61K31/355A61K47/10A61K47/02A61K9/10A61K47/26A61K47/40A61K9/143A61K31/353A61K45/06A61K9/107
Inventor WANG, LIANG-SHUNYANG, CHIH-CHIANGLIN, YU-HSUANFU, PING-CHUAN
Owner HUANA GLOBAL BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products